Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites
Authors:
- Mariana GalloMGMariana Gallo
- Elena FerrariElena Ferrari
- Federica BrugnoliFBFederica Brugnoli
- Anna TerrazzanATAnna Terrazzan
- Pietro AnconaPAPietro Ancona
- Stefano VoliniaStefano Volinia
- Valeria BertagnoloVBValeria Bertagnolo
- Carlo M. BergaminiCarlo M. Bergamini
- Alberto SpisniAlberto Spisni
- Thelma A. PertinhezTPThelma A. Pertinhez
- Nicoletta BianchiNicoletta Bianchi
Open Access
- 24 January 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 969
Abstract
Breast Cancer (BrCa) exhibits a high phenotypic heterogeneity, leading to the emergence of aggressive clones and the development of drug resistance. Considering the BrCa heterogeneity and that metabolic reprogramming is a cancer hallmark, we selected seven BrCa cell lines with diverse subtypes to provide their comprehensive metabolome characterization: five lines commonly used (SK-Br-3, T-47D, MCF-7, MDA-MB-436, and MDA-MB-231), and two patient-derived xenografts (Hbcx39 and Hbcx9). We characterized their endometabolomes using 1H-NMR spectroscopy. We found distinct metabolite profiles, with certain metabolites being common but differentially accumulated across the selected BrCa cell lines. High levels of glycine, lactate, glutamate, and formate, metabolites known to promote invasion and metastasis, were detected in all BrCa cells. In our experiment setting were identified unique metabolites to specific cell lines: xanthine and 2-oxoglutarate in SK-Br-3, 2-oxobutyrate in T-47D, cystathionine and glucose-1-phosphate in MCF-7, NAD+ in MDA-MB-436, isocitrate in MDA-MB-231, and NADP+ in Hbcx9. The unique and enriched metabolites enabled us to identify the metabolic pathways modulated in a cell-line-specific manner, which may represent potential candidate targets for therapeutic intervention. We believe this study may contribute to the functional characterization of BrCa cells and assist in selecting appropriate cell lines for drug-response studies.Keywords
Funding Information
- Fondo per l’Incentivazione alla Ricerca FIR2021 (FIR2191318, 2022-FAR.L-FIRD_medtras_Brugnoli)
- Nicoletta Bianchi and Fondo interdisciplinare per la Ricerca Dipartimentale FIRD2022 (FIR2191318, 2022-FAR.L-FIRD_medtras_Brugnoli)
- Laboratorio per le Tecnologie delle Terapie Avanzate of the University of Ferrara (FIR2191318, 2022-FAR.L-FIRD_medtras_Brugnoli)
This publication has 77 references indexed in Scilit:
- Recent advances in breast cancer cell line researchInternational Journal of Cancer, 2024
- Sample optimization for saliva 1H-NMR metabolic profilingAnalytical Biochemistry, 2022
- Defining the landscape of metabolic dysregulations in cancer metastasisClinical & Experimental Metastasis, 2021
- Breast Cancer Metabolomics Using NMR2019
- A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancerInternational Journal of Cancer, 2019
- Cystathionine: A novel oncometabolite in human breast cancerArchives of Biochemistry and Biophysics, 2016
- Glutamate enrichment as new diagnostic opportunity in breast cancerInternational Journal of Cancer, 2014
- 1H NMR analysis of choline metabolites in fine-needle-aspirate biopsies of breast cancerMagnetic Resonance Materials in Physics, Biology and Medicine, 2012
- Methionine gamma‐lyase: The unique reaction mechanism, physiological roles, and therapeutic applications against infectious diseases and cancersIUBMB Life, 2009
- Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studiesInternational Journal of Cancer, 2007